Rapid Diagnostics & Detection

Our interdisciplinary team of chemists, engineers and microbiologists work closely with key opinion leaders and industrial SMEs to develop rapid diagnostic tests and sensing technologies designed for end users in the field, clinical offices, hospital bedsides, and at home.
Zymeron develops three core technologies enabling nucleic acid tests (NAT) to be performed at the point of care/need with diagnostic accuracy matching centralized laboratory testing. Our NATs focus on infectious agents that impose health threats to the general population and in resource-limited regions and austere environments. Three core technologies include: hands-free sample processing, isothermal amplification, and automated testing and digital readout, in a fully integrated, all-in-one device.

“Laboratory Testing At Home”

Zymeron develops enabling technologies that permit nucleic acid amplification test at home that matches the sensitivity and specificity of lab-based tests such as PCR; thus the name “laboratory testing at home”.

At-home test or self-test is a device or a kit that an individual can obtain with a prescription or over the counter indicating self-testing as the intended use. The patient conducts specimen collection and the test on their own using simple instructions and obtains results in a short period of time. Self-test has the shortest time to result, but typically has seen poor sensitivity or specificity at prices higher than lab-based tests. Zymeron’s engineering team revolutionizes device design to achieve specimens processing, analyte amplification, and signal detection with the push of a button on disposable plastic devices. Our devices are designed for better usability, low interferences by patients or the environment (e.g. T, RH, lighting etc).

Zymeron’s at-home testing program develops tests for infectious diseases such as HIV, HCV, HPV, coronavirus, etc.

Point of Care Tests (POCT)

Our interdisciplinary team of chemists, biologists and engineers work closely with key opinion leaders and industrial SMEs to develop rapid diagnostic tests and assays designed for end users in the field, clinical offices and hospital bedsides. Zymeron’s POC test kits include a portable or handheld reader and single-use cartridges.

Zymeron also develops artificial intelligence assisted autonomous detection technologies leveraging the advances in image analysis and machine learning for more timely and accurate diagnostics. Such an autonomous detection system is inexpensive and amenable to use at any point of need, particularly useful in low resource settings.

Our POCT pipeline includes, therapeutic drug monitoring (TDM), nucleic acid amplification tests (NAAT), and immunoassays.

  • NAAT – HCV; Cocci, Histo and Blasto; Enteric and Diarrheal Pathogens; Legionella

  • TDM – First line TB drugs; ART adherence

  • Ab and Ag– CMV IgG/IgM; Dengue Serotyping

Rapid Microbiological Method

μSTF is an alternative rapid microbiological method based on lab-on-chip technology, ideal for sterility testing in biomanufacturing with less than 30 minutes of sample-to-result. μSTF has single-cell resolution, i.e. limit of detection is one microbial cell per sample. It is a nongrowth method, does not require any enrichment, culturing, staining, or incubation step. It is so rapid to provide near real-time, qualitative presence/absence readout.

μSTF can be used for any filterable product, for screening purpose to save time and money. The detection process is non-destructive, preserving the microbial contaminants from a positive screening test for further analysis including organism identification and strain typing if needed. Faster time to result enables manufacturers quicker product release to market, shorten the production cycle, improve productivity, free up working capital, and achieve greater return on investment.

μSTF is an automated, closed system requiring minimum training. The system is based on lab-on-chip detection technology and miniaturized instrumentation technique, and it is cost effective requiring very low upfront capital investment. Full automation from sample to result also eliminates inaccurate results induced by operator variations.

Compared to RMMs that require pre-enrichment such as nucleic acid amplification and metabolic markers, and cytometry-based methods that rely on expensive instruments, Zymeron’s μSTF is the best in class.